Search

Your search keyword '"Benafif, Sarah"' showing total 115 results

Search Constraints

Start Over You searched for: Author "Benafif, Sarah" Remove constraint Author: "Benafif, Sarah"
115 results on '"Benafif, Sarah"'

Search Results

1. Germline sequencing in men with metastatic castration-resistant prostate cancer from the BARCODE2 study reveals a wide range of pathogenic variants in DNA repair genes

2. Author Correction: The evolution of lung cancer and impact of subclonal selection in TRACERx

3. Durable responses to ATR inhibition with ceralasertib in tumors with genomic defects and high inflammation

4. The evolution of lung cancer and impact of subclonal selection in TRACERx

5. The use of germline genetic profiles to guide prostate cancer targeted screening and cancer care

6. 102 Hepatitis B and HIV screening prior to first systemic anticancer therapy (SACT) in an inner-city London thoracic cancer population.

7. 95 Lorlatinib in advanced ALK-rearranged NSCLC – real-world experience in a UK population

8. Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study

9. Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study

10. Efficacy and safety of dendrimer-enhanced (DEP) cabazitaxel (CTX-SPL9111) in advanced esophagogastric cancers in a phase 1/2 trial.

12. COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study

14. Data from Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer

15. Supplementary Data from Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer

17. Body composition and lung cancer-associated cachexia in TRACERx

18. The evolution of non-small cell lung cancer metastases in TRACERx

19. The evolution of lung cancer and impact of subclonal selection in TRACERx

20. Evolutionary characterization of lung adenocarcinoma morphology in TRACERx

21. Baseline results from the UK SIGNIFY study: a whole-body MRI screening study in TP53 mutation carriers and matched controls

22. Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study

23. Mortality Among Adults With Cancer Undergoing Chemotherapy or Immunotherapy and Infected With COVID-19

24. Allele-informed copy number evaluation of plasma DNA samples from metastatic prostate cancer patients: the PCF_SELECT consortium assay

27. Systemic Anti-Cancer Therapy and Metastatic Cancer Are Independent Mortality Risk Factors during Two UK Waves of the COVID-19 Pandemic at University College London Hospital

28. Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study

29. The BARCODE1 Pilot: a feasibility study of using germline single nucleotide polymorphisms to target prostate cancer screening

33. Specialist palliative and end-of-life care for patients with cancer and SARS-CoV-2 infection: a European perspective

34. COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumour subtype and patient demographics: a prospective cohort study

35. Cancer History and Systemic Anti-Cancer Therapy Independently Predict COVID-19 Mortality: A UK Tertiary Hospital Experience

36. Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer

37. The BARCODE1 Pilot: a feasibility study of using germline single nucleotide polymorphisms to target prostate cancer screening.

38. Presenting Features and Early Mortality from SARS-CoV-2 Infection in Cancer Patients during the Initial Stage of the COVID-19 Pandemic in Europe

39. Psychosocial effects of whole-body MRI screening in adult high-risk pathogenic TP53 mutation carriers: a case-controlled study (SIGNIFY)

40. Germline DNA Repair Gene Mutations in Young-onset Prostate Cancer Cases in the UK: Evidence for a More Extensive Genetic Panel

41. Psychosocial effects of whole-body MRI screening in adult high-risk pathogenic TP53 mutation carriers: a case-controlled study (SIGNIFY).

45. An update on PARP inhibitors for the treatment of cancer

46. Psychosocial effects of whole-body MRI screening in adult high-risk pathogenic TP53mutation carriers: a case-controlled study (SIGNIFY)

50. A first-in-human (FIH) dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of intravenous BAL101553, a novel microtubule inhibitor, in adult patients with advanced solid tumors.

Catalog

Books, media, physical & digital resources